A clinical approach to severe insulin resistance

Endocrine Development

Volumn 11, Issue , 2007, Pages 122-132

  Savage, D ^a   Semple, R ^a   Chatterjee, V ^a   Wales, J ^b   Ross, R ^c   O'Rahilly, S ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^c NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ALGORITHM; CASE REPORT; CLASSIFICATION; FEMALE; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; PEDIGREE; PHYSIOLOGY; REVIEW;

ADOLESCENT; ALGORITHMS; FEMALE; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; PEDIGREE;

EID: 39549116587     PISSN: 14217082     EISSN: 16622979     Source Type: Book Series    
DOI: 10.1159/000111067     Document Type: Conference Paper

References (18)

1. Savage DB, Agostini M, Barroso I, Gurnell M, Luan J, Meirhaeghe A, Harding AH, Ihrke G, Rajanayagam O, Soos MA, George S, Berger D, Thomas EL, Bell JD, Meeran K, Ross RJ, Vidal-Puig A, Wareham NJ, O'Rahilly S, Chatterjee VK, Schafer AJ: Digenic inheritance of severe insulin resistance in a human pedigree. Nat Genet 2002;31:379-384.
2. Flier JS, Moller DE, Moses AC, O'Rahilly S, Chaiken RL, Grigorescu F, Elahi D, Kahn BB, Weinreb JE, Eastman R: Insulin-mediated pseudoacromegaly: clinical and biochemical characterization of a syndrome of selective insulin resistance. J Clin Endocrinol Metab 1993;76:1533-1541.
3. Garg A: Acquired and inherited lipodystrophies. N Engl J Med 2004;350:1220-1234.
4. Semple RK, Soos MA, Luan J, Mitchell CS, Wilson JC, Gurnell M, Cochran EK, Gorden P, Chatterjee VK, Wareham NJ, O'Rahilly S: Elevated plasma adiponectin in humans with genetically defective insulin receptors. J Clin Endocrinol Metab 2006;91:3219-3223.
5. Musso C, Cochran E, Moran SA, Skarulis MC, Oral EA, Taylor S, Gorden P: Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective. Medicine (Baltimore) 2004;83:209-222.
6. Pacini G, Mari A: Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab 2003;17:305-322.
7. Coll AP, Morganstein D, Jayne D, Soos MA, O'Rahilly S, Burke J: Successful treatment of type B insulin resistance in a patient with otherwise quiescent systemic lupus erythematosus. Diabet Med 2005;22:814-815.
8. Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, Garg A: Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002;346:570-578.
9. Javor ED, Cochran EK, Musso C, Young JR, Depaoli AM, Gorden P: Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes 2005;54:1994-2002.
10. Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, Sanna V, Jebb SA, Perna F, Fontana S, Lechler RI, DePaoli AM, O'Rahilly S: Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002;110:1093-1103.
11. Savage DB, O'Rahilly S: Leptin: a novel therapeutic role in lipodystrophy. J Clin Invest 2002;109:1285-1286.
12. Kim JK, Fillmore JJ, Gavrilova O, Chao L, Higashimori T, Choi H, Kim HJ, Yu C, Chen Y, Qu X, Haluzik M, Reitman ML, Shulman GI: Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice. Diabetes 2003;52:1311-1318.
13. Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J, Herion D, Kleiner DE, Reynolds J, Premkumar A, Sumner AE, Hoofnagle J, Reitman ML, Taylor SI: Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000;133: 263-274.
14. Savage DB, Tan GD, Acerini CL, Jebb SA, Agostini M, Gurnell M, Williams RL, Umpleby AM, Thomas EL, Bell JD, Dixon AK, Dunne F, Boiani R, Cinti S, Vidal-Puig A, Karpe F, Chatterjee VK, O'Rahilly S: Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes 2003;52:910-917.
15. Cochran E, Musso C, Gorden P: The use of U-500 in patients with extreme insulin resistance. Diabetes Care 2005;28:1240-1244.
16. Jabri N, Schalch DS, Schwartz SL, Fischer JS, Kipnes MS, Radnik BJ, Turman NJ, Marcsisin VS, Guler HP: Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients. Diabetes 1994;43:369-374.
17. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3. Drugs R D 2005;6:120-127.
18. Cochran E, Young JR, Sebring N, DePaoli A, Oral EA, Gorden P: Efficacy of recombinant methionyl human leptin therapy for the extreme insulin resistance of the Rabson-Mendenhall syndrome. J Clin Endocrinol Metab 2004;89:1548-1554.